Portage Cost Of Revenue vs Gross Profit Analysis

PRTG Stock

USD 4.87 0.15 3.18%

Portage Biotech financial indicator trend analysis is much more than just breaking down Portage Biotech prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Portage Biotech is a good investment. Please check the relationship between Portage Biotech Cost Of Revenue and its Gross Profit accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Portage Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more detail on how to invest in Portage Stock please use our How to Invest in Portage Biotech guide.

Cost Of Revenue vs Gross Profit

Cost Of Revenue vs Gross Profit Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Portage Biotech Cost Of Revenue account and Gross Profit. At this time, the significance of the direction appears to have pay attention.

The correlation between Portage Biotech's Cost Of Revenue and Gross Profit is -0.99. Overlapping area represents the amount of variation of Cost Of Revenue that can explain the historical movement of Gross Profit in the same time period over historical financial statements of Portage Biotech, assuming nothing else is changed. The correlation between historical values of Portage Biotech's Cost Of Revenue and Gross Profit is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cost Of Revenue of Portage Biotech are associated (or correlated) with its Gross Profit. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Gross Profit has no effect on the direction of Cost Of Revenue i.e., Portage Biotech's Cost Of Revenue and Gross Profit go up and down completely randomly.

Correlation Coefficient

-0.99

Relationship Direction	Negative
Relationship Strength	Significant

View All Relationships

Cost Of Revenue

Cost of Revenue is found on Portage Biotech income statement and represents the costs associated with goods and services Portage Biotech provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Gross Profit

Gross profit is a required income statement account that reflects total revenue of Portage Biotech minus its cost of goods sold. It is profit before Portage Biotech operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.

Most indicators from Portage Biotech's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Portage Biotech current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Portage Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more detail on how to invest in Portage Stock please use our How to Invest in Portage Biotech guide.At this time, Portage Biotech's Issuance Of Capital Stock is most likely to increase significantly in the upcoming years. The Portage Biotech's current Enterprise Value is estimated to increase to about 365.1 M, while Selling General Administrative is projected to decrease to roughly 3.6 M.

	2021	2022	2023	2024 (projected)
Other Operating Expenses	15.6M	16.6M	18.3M	19.2M
Depreciation And Amortization	15.6M	1K	54K	51.3K

Other Operating Expenses Depreciation And Amortization

Portage Biotech fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Cash And Short Term Investments	Common Stock Shares Outstanding	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Short Long Term Debt Total	Non Currrent Assets Other	Other Assets	Non Current Liabilities Total	Other Current Assets	Short Term Debt	Accounts Payable	Net Receivables	Inventory	Intangible Assets	Good Will
Total Assets		0.19	0.33	0.99	-0.62	-0.37	0.13	0.52	0.98	0.19	0.31	-0.14	0.95	0.19	0.4	0.57	-0.07	0.94	0.96	-0.11	-0.29	-0.2	0.4	-0.31	0.69	0.77
Other Current Liab	0.19		0.93	0.15	0.24	0.07	-0.6	-0.09	0.23	-0.26	0.66	0.59	0.36	-0.17	0.64	-0.03	-0.09	0.19	0.26	0.72	-0.58	0.09	0.47	-0.67	0.26	0.04
Total Current Liabilities	0.33	0.93		0.26	0.15	0.11	-0.61	-0.08	0.38	-0.32	0.69	0.48	0.49	-0.24	0.72	0.24	-0.17	0.35	0.39	0.62	-0.51	0.26	0.39	-0.6	0.36	0.15
Total Stockholder Equity	0.99	0.15	0.26		-0.67	-0.41	0.13	0.55	0.94	0.33	0.31	-0.13	0.93	0.33	0.4	0.5	-0.01	0.87	0.94	-0.12	-0.28	-0.25	0.39	-0.33	0.71	0.71
Property Plant And Equipment Net	-0.62	0.24	0.15	-0.67		0.28	-0.38	-0.38	-0.57	-0.35	0.01	0.38	-0.51	-0.33	0.0	-0.33	-0.32	-0.49	-0.56	0.39	-0.14	0.14	-0.2	-0.06	-0.52	-0.57
Net Debt	-0.37	0.07	0.11	-0.41	0.28		0.25	-0.97	-0.34	-0.17	-0.4	-0.18	-0.43	-0.18	-0.43	0.26	-0.28	-0.26	-0.45	-0.04	0.4	0.15	-0.01	0.56	-0.33	-0.3
Retained Earnings	0.13	-0.6	-0.61	0.13	-0.38	0.25		-0.18	0.11	0.16	-0.86	-0.46	-0.09	0.12	-0.85	0.23	-0.11	0.2	-0.01	-0.47	0.65	-0.27	0.03	0.73	-0.21	0.31
Cash	0.52	-0.09	-0.08	0.55	-0.38	-0.97	-0.18		0.5	0.16	0.39	0.11	0.56	0.16	0.44	-0.04	0.26	0.42	0.59	-0.03	-0.36	-0.13	-0.02	-0.48	0.42	0.45
Non Current Assets Total	0.98	0.23	0.38	0.94	-0.57	-0.34	0.11	0.5		0.0	0.31	-0.14	0.97	0.0	0.41	0.61	-0.08	0.96	0.98	-0.11	-0.3	-0.14	0.43	-0.31	0.62	0.8
Cash And Short Term Investments	0.19	-0.26	-0.32	0.33	-0.35	-0.17	0.16	0.16	0.0		0.0	-0.14	0.0	0.99	-0.04	-0.11	0.01	-0.01	0.02	-0.17	0.09	-0.36	-0.16	0.01	0.44	-0.05
Common Stock Shares Outstanding	0.31	0.66	0.69	0.31	0.01	-0.4	-0.86	0.39	0.31	0.0		0.25	0.49	0.03	0.96	-0.01	0.07	0.23	0.41	0.29	-0.77	0.07	0.17	-0.83	0.56	0.07
Other Stockholder Equity	-0.14	0.59	0.48	-0.13	0.38	-0.18	-0.46	0.11	-0.14	-0.14	0.25		-0.01	-0.02	0.31	-0.32	0.0	-0.2	-0.05	0.94	-0.16	0.36	0.04	-0.44	-0.18	-0.3
Total Liab	0.95	0.36	0.49	0.93	-0.51	-0.43	-0.09	0.56	0.97	0.0	0.49	-0.01		0.01	0.59	0.52	0.02	0.88	0.99	0.03	-0.45	-0.11	0.44	-0.48	0.64	0.69
Total Current Assets	0.19	-0.17	-0.24	0.33	-0.33	-0.18	0.12	0.16	0.0	0.99	0.03	-0.02	0.01		-0.01	-0.14	0.01	-0.01	0.04	-0.05	0.07	-0.33	-0.13	-0.04	0.44	-0.07
Common Stock	0.4	0.64	0.72	0.4	0.0	-0.43	-0.85	0.44	0.41	-0.04	0.96	0.31	0.59	-0.01		0.09	0.1	0.3	0.52	0.35	-0.75	0.11	0.18	-0.83	0.57	0.12
Short Long Term Debt Total	0.57	-0.03	0.24	0.5	-0.33	0.26	0.23	-0.04	0.61	-0.11	-0.01	-0.32	0.52	-0.14	0.09		-0.16	0.64	0.52	-0.24	0.17	0.19	-0.18	0.35	0.38	0.56
Non Currrent Assets Other	-0.07	-0.09	-0.17	-0.01	-0.32	-0.28	-0.11	0.26	-0.08	0.01	0.07	0.0	0.02	0.01	0.1	-0.16		-0.25	0.04	-0.01	0.01	-0.22	0.03	-0.08	0.25	0.13
Other Assets	0.94	0.19	0.35	0.87	-0.49	-0.26	0.2	0.42	0.96	-0.01	0.23	-0.2	0.88	-0.01	0.3	0.64	-0.25		0.88	-0.15	-0.22	-0.13	0.37	-0.2	0.6	0.85
Non Current Liabilities Total	0.96	0.26	0.39	0.94	-0.56	-0.45	-0.01	0.59	0.98	0.02	0.41	-0.05	0.99	0.04	0.52	0.52	0.04	0.88		-0.04	-0.4	-0.13	0.42	-0.42	0.62	0.71
Other Current Assets	-0.11	0.72	0.62	-0.12	0.39	-0.04	-0.47	-0.03	-0.11	-0.17	0.29	0.94	0.03	-0.05	0.35	-0.24	-0.01	-0.15	-0.04		-0.2	0.27	0.11	-0.45	-0.08	-0.24
Short Term Debt	-0.29	-0.58	-0.51	-0.28	-0.14	0.4	0.65	-0.36	-0.3	0.09	-0.77	-0.16	-0.45	0.07	-0.75	0.17	0.01	-0.22	-0.4	-0.2		0.26	-0.33	0.84	-0.34	-0.05
Accounts Payable	-0.2	0.09	0.26	-0.25	0.14	0.15	-0.27	-0.13	-0.14	-0.36	0.07	0.36	-0.11	-0.33	0.11	0.19	-0.22	-0.13	-0.13	0.27	0.26		-0.37	0.13	-0.3	-0.26
Net Receivables	0.4	0.47	0.39	0.39	-0.2	-0.01	0.03	-0.02	0.43	-0.16	0.17	0.04	0.44	-0.13	0.18	-0.18	0.03	0.37	0.42	0.11	-0.33	-0.37		-0.49	0.17	0.28
Inventory	-0.31	-0.67	-0.6	-0.33	-0.06	0.56	0.73	-0.48	-0.31	0.01	-0.83	-0.44	-0.48	-0.04	-0.83	0.35	-0.08	-0.2	-0.42	-0.45	0.84	0.13	-0.49		-0.39	-0.04
Intangible Assets	0.69	0.26	0.36	0.71	-0.52	-0.33	-0.21	0.42	0.62	0.44	0.56	-0.18	0.64	0.44	0.57	0.38	0.25	0.6	0.62	-0.08	-0.34	-0.3	0.17	-0.39		0.65
Good Will	0.77	0.04	0.15	0.71	-0.57	-0.3	0.31	0.45	0.8	-0.05	0.07	-0.3	0.69	-0.07	0.12	0.56	0.13	0.85	0.71	-0.24	-0.05	-0.26	0.28	-0.04	0.65

Click cells to compare fundamentals

Portage Biotech Account Relationship Matchups

Portage Biotech fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	173.2M	174.9M	194.7M	99.1M	7.8M	7.4M
Other Current Liab	1.9M	2.9M	595K	1.6M	2.4M	2.5M
Total Current Liabilities	2.6M	3.2M	783K	1.9M	2.9M	3.0M
Total Stockholder Equity	96.5M	101.4M	121.2M	76.0M	4.0M	3.8M
Net Debt	509K	(2.6M)	(23.4M)	(10.5M)	(5.0M)	(4.7M)
Retained Earnings	(22.3M)	(38.1M)	(55.0M)	(159.6M)	(239.3M)	(227.4M)
Cash	3.2M	2.8M	23.4M	10.5M	5.0M	3.2M
Non Current Assets Total	169.4M	169.9M	169.8M	85.5M	84K	79.8K
Cash And Short Term Investments	3.2M	2.8M	23.4M	10.5M	5.0M	6.1M
Common Stock Shares Outstanding	11.0M	11.7M	13.1M	16.1M	20.3M	21.4M
Liabilities And Stockholders Equity	173.2M	174.9M	194.7M	99.1M	7.8M	7.4M
Other Stockholder Equity	58K	8.0M	16.9M	21.2M	24.4M	13.3M
Total Liab	27.5M	27.3M	29.2M	23.7M	4.5M	6.1M
Total Current Assets	3.8M	4.9M	24.8M	13.7M	7.7M	7.1M
Common Stock	117.8M	130.6M	158.3M	218.8M	219.5M	230.5M
Short Long Term Debt Total	3.7M	3.7M	150K	47K	54.1K	51.3K
Non Currrent Assets Other	34K	58K	36K	877K	49K	46.6K
Other Assets	117.4M	117.4M	117.4M	1.0	1.15	1.09
Non Current Liabilities Total	25.0M	24.1M	28.4M	21.9M	1.6M	1.5M
Other Current Assets	14K	1.5M	1.3M	2.4M	2.6M	2.8M
Accounts Payable	343K	113K	188K	274K	482K	304.4K
Net Receivables	60K	2.2M	209K	682K	39K	37.1K
Accumulated Other Comprehensive Income	32K	82K	958K	(4.3M)	23.8M	25.0M
Net Tangible Assets	56.4M	53.2M	58.1M	77.9M	89.6M	57.7M
Long Term Investments	6.4M	8.6M	9.1M	9.1M	2.9M	0.0
Net Invested Capital	100.2M	101.6M	121.2M	76.0M	4.0M	3.8M
Net Working Capital	1.2M	1.7M	24.0M	11.8M	4.8M	8.8M
Capital Stock	117.8M	130.6M	158.3M	218.8M	219.5M	176.2M

Currently Active Assets on Macroaxis

ESRT	Empire State Realty
C	Citigroup
C	Citigroup
GOOG	Alphabet Inc Class C
DD	Dupont De Nemours

When determining whether Portage Biotech is a strong investment it is important to analyze Portage Biotech's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Portage Biotech's future performance. For an informed investment choice regarding Portage Stock, refer to the following important reports:

How To Invest In Portage

Details

Is Portage Stock a good investment?

Details

What is Portage Biotech's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Portage Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more detail on how to invest in Portage Stock please use our How to Invest in Portage Biotech guide.

You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Portage Biotech. If investors know Portage will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Portage Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

24.4

Return On Assets

(0.19)

Return On Equity

(1.91)

The market value of Portage Biotech is measured differently than its book value, which is the value of Portage that is recorded on the company's balance sheet. Investors also form their own opinion of Portage Biotech's value that differs from its market value or its book value, called intrinsic value, which is Portage Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Portage Biotech's market value can be influenced by many factors that don't directly affect Portage Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Portage Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Portage Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Portage Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Portage Cost Of Revenue vs Gross Profit Analysis

Cost Of Revenue vs Gross Profit

Cost Of Revenue vs Gross Profit Correlation Analysis

Correlation Coefficient

Cost Of Revenue

Gross Profit

Portage Biotech fundamental ratios Correlations

Portage Biotech Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Portage Biotech fundamental ratios Accounts

Currently Active Assets on Macroaxis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 0.99	Total Assets
Total Current Assets	+ 0.99	Cash And Short Term Investments
Non Current Liabilities Total	+ 0.99	Total Liab
Non Current Assets Total	+ 0.98	Total Assets
Non Current Liabilities Total	+ 0.98	Non Current Assets Total
Total Liab	+ 0.97	Non Current Assets Total

Cash	- 0.97	Net Debt
Common Stock Shares Outstanding	- 0.86	Retained Earnings
Common Stock	- 0.85	Retained Earnings
Inventory	- 0.83	Common Stock
Inventory	- 0.83	Common Stock Shares Outstanding
Short Term Debt	- 0.77	Common Stock Shares Outstanding